Updates in non-small cell lung cancer

被引：65

作者：

Walker, Suzanne ^{[1
,2
]}

机构：

[1] Penn Presbyterian Med Ctr, Abramson Canc Ctr, Philadelphia, PA USA

[2] Univ Penn, Sch Nursing, Oncol Adv Practice Nursing Program, Philadelphia, PA 19104 USA

来源：

CLINICAL JOURNAL OF ONCOLOGY NURSING | 2008年 / 12卷 / 04期

关键词：

D O I：

10.1188/08.CJON.587-596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer diagnoses. Five-year survival remains at 15%, but new strategies for prevention, early detection, and treatment may improve survival rates. This article provides an overview of updates in NSCLC, with an emphasis on advances in treatment strategies. Newer targeted therapies, as well as advances in genetic blueprinting, will be discussed. Nurses play a pivotal role in the assessment and management of patients with NSCLC and, therefore, must remain abreast of the most current prevention, screening, and treatment options.

引用

页码：587 / 596

页数：10

共 86 条

[41]

Hanna NH, 2007, J CLIN ONCOL, V25

[42] Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer [J].

Herbst, RS ;

Johnson, DH ;

Mininberg, E ;

Carbone, DP ;

Henderson, T ;

Kim, ES ;

Blumenschein, G ;

Lee, JJ ;

Liu, DD ;

Truong, MT ;

Hong, WK ;

Tran, H ;

Tsao, A ;

Xie, D ;

Ramies, DA ;

Mass, R ;

Seshagiri, S ;

Eberhard, DA ;

Kelley, SK ;

Sandler, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2544-2555

[43] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[44]

Jatoi Aminah, 2006, J Support Oncol, V4, P499

[45] Cancer statistics, 2008 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Hao, Yongping ;

Xu, Jiaquan ;

Murray, Taylor ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) :71-96

[46] Palliative care [J].

Kvale, PA ;

Simoff, M ;

Prakash, UBS .

CHEST, 2003, 123 (01) :284S-311S

[47]

Langer CJ, 2002, JNCI-J NATL CANCER I, V94, P173

[48] ROLE OF THE HUMAN ERCC-1 GENE IN GENE-SPECIFIC REPAIR OF CISPLATIN-INDUCED DNA-DAMAGE [J].

LARMINAT, F ;

BOHR, VA .

NUCLEIC ACIDS RESEARCH, 1994, 22 (15) :3005-3010

[49] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer [J].

Le Chevalier, T ;

Arriagada, R ;

Le Péchoux, C ;

Grunenwald, D ;

Dunant, A ;

Pignon, JP ;

Tarayre, M ;

Abratt, R ;

Arriagada, R ;

Bergman, B ;

Gralla, R ;

Grunenwald, D ;

Le Chevalier, T ;

Orlowski, T ;

Papadakis, E ;

Pinel, MIS ;

Araujo, C ;

Della Torre, H ;

de Solchaga, MM ;

Abdi, E ;

Blum, R ;

Ball, D ;

Basser, R ;

De Boer, R ;

Bishop, J ;

Brigham, B ;

Davis, S ;

Fox, D ;

Richardson, G ;

Wyld, D ;

Pirker, R ;

Humblet, Y ;

Delaunois, L ;

Van Meerbeeck, JP ;

Germonpre, P ;

Vansteenkiste, J ;

Nackaerts, K ;

Pinel, MIS ;

Vauthier, G ;

Younes, RN ;

Arriagada, R ;

Baeza, R ;

Carvajal, P ;

Kleinman, S ;

Orlandi, L ;

Castro, C ;

Godoy, J ;

Kosatova, K ;

Gaafar, R ;

Azarian, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) :351-360

[50]

LIU B, 2006, J CLIN ONCOL S, V24, pS676

← 1 2 3 4 5 6 7 8 9 →